이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

NATCO Pharma 관리

관리 기준 확인 1/4

NATCO Pharma's CEO는 Rajeev Nannapaneni, Jun2012 에 임명되었습니다 의 임기는 12.17 년입니다. 는 ₹ 1.64B 가치에 해당하는 회사 주식의 0.63% 직접 소유합니다. 1.64B. 경영진과 이사회의 평균 재임 기간은 각각 7.5 년과 9.6 년입니다.

주요 정보

Rajeev Nannapaneni

최고 경영자

₹98.7m

총 보상

CEO 급여 비율	n/a
CEO 임기	12.3yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	7.6yrs
이사회 평균 재임 기간	2.1yrs

최근 관리 업데이트

Recent updates

NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

Aug 13

If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

Jul 15

NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

Jun 30

NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

Jun 14

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

May 30

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

Feb 18

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Feb 17

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jan 25

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Jan 09

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Dec 13

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Sep 30

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

Sep 12

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Aug 12

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jul 16

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Apr 20

Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

Dec 20

NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Aug 12

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Jun 23

Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

Jun 02

CEO

Rajeev Nannapaneni (47 yo)

12.3yrs

테뉴어

₹98,670,000

보상

Sri Rajeev Nannapaneni serves as Chief Executive Officer at NATCO Pharma Limited since April 1, 2022 and also served as Vice Chairman since June 1, 2012 until April 1, 2022 and serves as its Vice Chairman...

리더십 팀

이름	위치	테뉴어	보상	소유권
Venkaiah Nannapaneni	MD & Chairman	43yrs	₹100.77m	25.1% ₹ 63.5b
Rajeev Nannapaneni	CEO & Vice Chairman	12.3yrs	₹98.67m	0.63% ₹ 1.6b
S. V. V. Appa Rao	Chief Financial Officer	8.6yrs	₹13.36m	데이터 없음
Donthineni Rao	President of Technical Affairs & Whole Time Director	no data	₹33.69m	0.030% ₹ 76.5m
Chekuri Ramesh	Company Secretary & Compliance Officer	2.4yrs	₹2.61m	데이터 없음
Potluri Prasad	Executive VP of Corporate Engineering Services & Whole Time Director	no data	₹20.16m	0.023% ₹ 58.1m
Pavan Bhat	Executive VP of Technical Operations & Director	7.6yrs	₹32.12m	0.013% ₹ 32.9m
Nadella Rao	VP & Head of Operations	no data	데이터 없음	데이터 없음
N. Rao	Executive Vice President of Corporate Affairs	no data	데이터 없음	데이터 없음
James Rajakumar	Vice President of Marketing & Sales - Domestic	less than a year	데이터 없음	데이터 없음
A. Lakshminarayana	Senior Vice President of HR & Organisational Development	no data	데이터 없음	0.0062% ₹ 15.7m
M. Reddy	Executive Vice President of R&D	30.4yrs	데이터 없음	0.025% ₹ 62.3m

7.6yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 관리: NATCOPHARM 의 관리팀은 노련하고 경험 (평균 재직 기간 7.5 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Venkaiah Nannapaneni	MD & Chairman	43yrs	₹100.77m	25.1% ₹ 63.5b
Rajeev Nannapaneni	CEO & Vice Chairman	18.8yrs	₹98.67m	0.63% ₹ 1.6b
Donthineni Rao	President of Technical Affairs & Whole Time Director	9.6yrs	₹33.69m	0.030% ₹ 76.5m
Potluri Prasad	Executive VP of Corporate Engineering Services & Whole Time Director	9.8yrs	₹20.16m	0.023% ₹ 58.1m
Pavan Bhat	Executive VP of Technical Operations & Director	2.1yrs	₹32.12m	0.013% ₹ 32.9m
Madireddi Naidu	Independent Director	9.6yrs	₹330.00k	데이터 없음
Agnihotra Dakshina Chavali	Independent Director	less than a year	데이터 없음	데이터 없음
Dronadula Bhaskar	Independent Director	less than a year	데이터 없음	데이터 없음
Lakshminarayana Bolisetty	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음
Kantipudi Suma	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음
Nitin Jain	Independent Non-Executive Director	less than a year	데이터 없음	데이터 없음

2.1yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: NATCOPHARM 의 이사회는 경험(평균 재직 기간 2.1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

NATCO Pharma 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Insider recently sold ₹30m worth of stock

High number of new directors

Less than half of directors are independent

NATCO Pharma Limited Announces Term Completion of Directors

NATCO Pharma Limited, Annual General Meeting, Sep 30, 2024

NATCO Pharma Limited Announces Resignation of Sanivarapu Ravi Prakash Reddy as Senior Vice President - Operations

Recent updates

Insider recently sold ₹30m worth of stock

High number of new directors

Natco Pharma Limited Submits Abbreviated New Drug Application Containing A Paragraph IV Certification with the U.S. Food and Drug Administration

Less than half of directors are independent

New minor risk - Insider selling

Consensus EPS estimates increase by 14%

Price target increased by 11% to ₹1,180

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2024-25, Payable from August 30, 2024

Dividend of ₹3.00 announced

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

NATCO Pharma Limited Announces Term Completion of Directors

NATCO Pharma Limited, Annual General Meeting, Sep 30, 2024

NATCO Pharma Limited Announces Resignation of Sanivarapu Ravi Prakash Reddy as Senior Vice President - Operations

NATCO Pharma Limited to Report Q1, 2025 Results on Aug 12, 2024

If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

Board Member recently sold ₹6.0m worth of stock

NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

Investor sentiment improves as stock rises 21%

Consensus EPS estimates increase by 14%

Price target increased by 9.1% to ₹1,064

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

New major risk - Revenue and earnings growth

Full year 2024 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited to Report Q4, 2024 Results on May 27, 2024

Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Now 22% undervalued

Now 20% undervalued

Consensus EPS estimates increase by 17%

Investor sentiment improves as stock rises 16%

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Upcoming dividend of ₹1.25 per share

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Price target increased by 8.9% to ₹895

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024

NATCO Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Board Member recently sold ₹8.0m worth of stock

Insider recently sold ₹1.2m worth of stock

Board Member recently sold ₹7.9m worth of stock

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Insider recently sold ₹1.6m worth of stock

NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

NATCO Pharma Limited, Annual General Meeting, Sep 29, 2023

Upcoming dividend of ₹7.00 per share at 0.7% yield

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Price target increased by 9.6% to ₹734

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings: EPS exceeds analyst expectations

NATCO Pharma Limited to Report Q1, 2024 Results on Aug 09, 2023

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

NATCO Pharma Limited (NSEI:NATCOPHARM) agreed to acquire Zista Pharma Limited for $3 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Insider recently bought ₹161k worth of stock

NATCO Pharma Limited Files Generic Olaparib Tablets in USA

Upcoming dividend of ₹1.25 per share at 1.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited Approves Third Interim Dividend for the Financial Year 2022-23, Payable on March 1, 2023

NATCO Pharma Limited to Report Q3, 2023 Results on Feb 09, 2023